603717.SH
天域生物
SSE · Industrials · Engineering & Construction · CN
CNY 6.31
−0.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 654.2M | 725.6M | 801.5M | 670.5M | 944.9M |
| Cost of Revenue | 680.3M | 726.5M | 714.7M | 901.2M | 837.9M |
| Gross Profit | (26.0M) | (906.5K) | 86.8M | (230.8M) | 107.0M |
| Operating Expenses | |||||
| R&D Expense | 11.6M | 13.9M | 11.6M | 13.9M | 26.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 77.6M | 79.7M | 105.1M | 92.4M | 83.9M |
| Selling & Marketing Expense | 4.4M | 4.4M | 4.5M | 3.0M | 4.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 102.7M | 109.4M | 133.4M | 130.2M | 137.1M |
| Cost and Expenses | 783.0M | 835.9M | 848.1M | 1.0B | 975.0M |
| Operating Income (EBIT) | (135.4M) | (101.9M) | (89.7M) | (569.4M) | (323.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (130.3M) | (96.2M) | (87.2M) | (578.6M) | (316.8M) |
| Income Tax Expense | 5.4M | 5.8M | (315.3K) | (12.7M) | (48.3M) |
| Bottom Line | |||||
| Net Income | (131.2M) | (106.9M) | (107.4M) | (461.6M) | (312.2M) |
| Earnings from Cont. Ops | (135.7M) | (102.0M) | (86.8M) | (565.9M) | (268.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (131.2M) | (106.9M) | (107.4M) | (461.6M) | (312.2M) |
| Per Share | |||||
| Basic EPS | (CN¥0.45) | (CN¥0.37) | (CN¥0.37) | (CN¥1.59) | (CN¥1.08) |
| Diluted EPS | (CN¥0.45) | (CN¥0.37) | (CN¥0.37) | (CN¥1.59) | (CN¥1.08) |
| Revenue Per Share | CN¥2.26 | CN¥2.50 | CN¥2.76 | CN¥2.31 | CN¥3.26 |
| Shares | |||||
| Basic Shares Outstanding | 289.8M | 290.2M | 290.2M | 290.2M | 290.1M |
| Diluted Shares Outstanding | 289.8M | 290.2M | 290.2M | 290.2M | 290.1M |
| Profitability Metrics | |||||
| EBITDA | — | (58.6M) | (50.4M) | (536.0M) | (307.8M) |
| D&A | — | 43.3M | 39.2M | 33.4M | 15.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026